Targeted versus universal prevention. a resource allocation model to prioritize cardiovascular prevention

BackgroundDiabetes mellitus brings an increased risk for cardiovascular complications and patients profit from prevention. This prevention also suits the general population. The question arises what is a better strategy: target the general population or diabetes patients.MethodsA mathematical programming model was developed to calculate optimal allocations for the Dutch population of the following interventions: smoking cessation support, diet and exercise to reduce overweight, statins, and medication to reduce blood pressure. Outcomes were total lifetime health care costs and QALYs. Budget sizes were varied and the division of resources between the general population and diabetes patients was assessed.ResultsFull implementation of all interventions resulted in a gain of 560,000 QALY at a cost of €640 per capita, about €12,900 per QALY on average. The large majority of these QALY gains could be obtained at incremental costs below €20,000 per QALY. Low or high budgets (below €9 or above €100 per capita) were predominantly spent in the general population. Moderate budgets were mostly spent in diabetes patients.ConclusionsMajor health gains can be realized efficiently by offering prevention to both the general and the diabetic population. However, a priori setting a specific distribution of resources is suboptimal. Resource allocation models allow accounting for capacity constraints and program size in addition to efficiency.

[1]  J. Richardson,et al.  Cost-Effectiveness of the Primary Prevention of Non-Insulin Dependent Diabetes Mellitus , 1997 .

[2]  O. Franco,et al.  Cost effectiveness of statins in coronary heart disease , 2005, Journal of Epidemiology and Community Health.

[3]  W. Groot,et al.  Costs of the 'Hartslag Limburg' community heart health intervention , 2006, BMC public health.

[4]  M K Campbell,et al.  Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. , 2004, Health technology assessment.

[5]  Oluf Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[6]  Rudolf T Hoogenveen,et al.  Dynamic effects of smoking cessation on disease incidence, mortality and quality of life: The role of time since cessation , 2008, Cost effectiveness and resource allocation : C/E.

[7]  Rudolf T Hoogenveen,et al.  Chronic disease projections in heterogeneous ageing populations: approximating multi-state models of joint distributions by modelling marginal distributions. , 2010, Mathematical medicine and biology : a journal of the IMA.

[8]  E. Feskens,et al.  Lifestyle intervention according to general recommendations improves glucose tolerance. , 2003, Obesity research.

[9]  Ping Zhang,et al.  Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[10]  Reiner Leidl,et al.  A Decision Chart for Assessing and Improving the Transferability of Economic Evaluation Results Between Countries , 2012, PharmacoEconomics.

[11]  S. Ward,et al.  A systematic review and economic evaluation of statins for the prevention of coronary events. , 2007, Health technology assessment.

[12]  R. Hoogenveen,et al.  Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study. , 2005, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  N. Chaturvedi The burden of diabetes and its complications: trends and implications for intervention. , 2007, Diabetes research and clinical practice.

[14]  P. Engelfriet,et al.  Lipid-lowering treatment for all could substantially reduce the burden of macrovascular complications of diabetes patients in the Netherlands , 2008, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[15]  G. Bray,et al.  Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes , 2007, Diabetes Care.

[16]  Hendriek C Boshuizen,et al.  Combining risk estimates from observational studies with different exposure cutpoints: a meta-analysis on body mass index and diabetes type 2. , 2006, American journal of epidemiology.

[17]  M A Koopmanschap,et al.  Resource consumption and costs in Dutch patients with Type 2 diabetes mellitus. Results from 29 general practices , 2002, Diabetic medicine : a journal of the British Diabetic Association.

[18]  A. Gafni,et al.  Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. , 2006, Social science & medicine.

[19]  C. Murray,et al.  The global burden of disease in 1990: summary results, sensitivity analysis and future directions. , 1994, Bulletin of the World Health Organization.

[20]  Jantine Schuit,et al.  The costs, effects and cost-effectiveness of counteracting overweight on a population level. A scientific base for policy targets for the Dutch national plan for action. , 2008, Preventive medicine.

[21]  P. Engelfriet,et al.  The cost-effectiveness of implementing a new guideline for cardiovascular risk management in primary care in the Netherlands , 2009, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[22]  D. Greenwood,et al.  Structured patient education: the Diabetes X‐PERT Programme makes a difference , 2006, Diabetic medicine : a journal of the British Diabetic Association.

[23]  Anke Richter,et al.  Optimal Allocation of Resources across Four Interventions for Type 2 Diabetes , 2002, Medical decision making : an international journal of the Society for Medical Decision Making.

[24]  Neil Chapman,et al.  Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. , 2005, Archives of internal medicine.

[25]  N. Graves,et al.  A review of the cost-effectiveness of face-to-face behavioural interventions for smoking, physical activity, diet and alcohol , 2007, Chronic illness.

[26]  P. Clarke,et al.  The economic analyses of the UK prospective diabetes study , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[27]  R. Hutubessy,et al.  Lifetime health effects and costs of diabetes treatment. , 2003, The Netherlands journal of medicine.

[28]  J. Bottomley,et al.  Pharmaco-economic issues for diabetes therapy. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[29]  Amiram Gafni,et al.  Optimizing a portfolio of health care programs in the presence of uncertainty and constrained resources. , 2003, Social science & medicine.

[30]  J. Shearer,et al.  Cost effectiveness analysis of smoking cessation interventions , 2006, Australian and New Zealand journal of public health.

[31]  P. van Baal,et al.  Unrelated medical care in life years gained and the cost utility of primary prevention: in search of a 'perfect' cost-utility ratio. , 2007, Health economics.

[32]  C. Baan,et al.  Cost Effectiveness of Preventive Interventions in Type 2 Diabetes Mellitus , 2012, PharmacoEconomics.

[33]  T. Marshall,et al.  Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study , 2002, BMJ : British Medical Journal.

[34]  S. Golder,et al.  Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment , 2012, PharmacoEconomics.

[35]  R. Koopman,et al.  Impact of the population at risk of diabetes on projections of diabetes burden in the United States: an epidemic on the way , 2006, Diabetologia.

[36]  E. Feskens,et al.  Cost-Effectiveness of Lifestyle Modification in Diabetic Patients , 2009, Diabetes Care.

[37]  R. Collins,et al.  Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.

[38]  R. Hoogenveen,et al.  Lifestyle Interventions Are Cost-Effective in People With Different Levels of Diabetes Risk , 2007, Diabetes Care.